Its activity is employed as an important predictor of immunotherapy response (Ferns et al., 2015; Liu et al., 2016; Seeber et al., 2018), and the inhibitors of IDO1 are widely studied in tumor combination therapy (Peng et al., 2018; Zhang et al., 2020). This evidence concerns the gene IDO1 and neoplasm.